Abstract:Background: Several studies have explored the predictive performance of machine learning-based breast cancer risk prediction models and have shown controversial conclusions. Thus, the performance of the current machine learning-based breast cancer risk prediction models and their benefits and weakness need to be evaluated for the future development of feasible and efficient risk prediction models. Objective: The aim of this review was to assess the performance and the clinical feasibility of the currently available machine learning-based breast cancer risk prediction models. Methods: We searched for papers published until June 9, 2021, on machine learning-based breast cancer risk prediction models in PubMed, Embase, and Web of Science. Studies describing the development or validation models for predicting future breast cancer risk were included. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was used to assess the risk of bias and the clinical applicability of the included studies. The pooled area under the curve (AUC) was calculated using the DerSimonian and Laird random-effects model. Results: A total of 8 studies with 10 data sets were included. Neural network was the most common machine learning method for the development of breast cancer risk prediction models. The pooled AUC of the machine learning-based optimal risk prediction model reported in each study was 0.73 (95% CI 0.66-0.80; approximate 95% prediction interval 0.56-0.96), with a high level of heterogeneity between studies (Q=576.07, I2=98.44%; P<.001). The results of head-to-head comparison of the performance difference between the 2 types of models trained by the same data set showed that machine learning models had a slightly higher advantage than traditional risk factor-based models in predicting future breast cancer risk. The pooled AUC of the neural network-based risk prediction model was higher than that of the nonneural network-based optimal risk prediction model (0.71 vs 0.68, respectively). Subgroup analysis showed that the incorporation of imaging features in risk models resulted in a higher pooled AUC than the nonincorporation of imaging features in risk models (0.73 vs 0.61; Pheterogeneity=.001, respectively). The PROBAST analysis indicated that many machine learning models had high risk of bias and poorly reported calibration analysis. Conclusions: Our review shows that the current machine learning-based breast cancer risk prediction models have some technical pitfalls and that their clinical feasibility and reliability are unsatisfactory.

Scope, Design, and Reporting of Prediction Models for Antineoplastic Drugs‐related Adverse Drug Events: A Systematic Review of Machine Learning and Traditional Modeling

Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis

Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records

Abstract 4923: A systematic framework for predicting adverse drug reaction signals using medical data

Advances In Machine Learning Prediction Of Toxicological Properties And Adverse Drug Reactions Of Pharmaceutical Agents

Abstract 3157: Prediction of adverse drug reactions of anti-breast cancer drugs using machine learning

Predicting Adverse Drug Events in Chinese Pediatric Inpatients With the Associated Risk Factors: A Machine Learning Study

Review of machine learning and deep learning models for toxicity prediction

How Platinum-Induced Nephrotoxicity occurs? Machine Learning Prediction in Non-small Cell Lung Cancer Patients

Electronic health record-based prediction models for in-hospital adverse drug event diagnosis or prognosis: a systematic review

An Assessment of the Predictive Performance of Current Machine Learning-Based Breast Cancer Risk Prediction Models: Systematic Review

Evaluating the Effectiveness of Artificial Intelligence in Predicting Adverse Drug Reactions among Cancer Patients: A Systematic Review and Meta-Analysis

Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis

In silico prediction of potential drug-induced nephrotoxicity with machine learning methods

Machine Learning Models for Risk Prediction of Cancer Associated Thrombosis: A Systematic Review and Meta-Analysis

Machine learning for adverse event prediction in outpatient parenteral antimicrobial therapy: a scoping review

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials

Can machine learning predict pharmacotherapy outcomes? An application study in osteoporosis

A Review of Approaches for Predicting Drug–Drug Interactions Based on Machine Learning

Machine Learning Prediction of On/Off Target-driven Clinical Adverse Events

Data Mining and Analytical Models to Predict and Identify Adverse Drug-drug Interactions